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Abstract
Background: Vorinostat, a histone deacetylase (HDAC) inhibitor, is a promising agent for cancer therapy.
Combining vorinostat with cisplatin may relax the chromatin structure and facilitate the accessibility of cisplatin,
thus enhancing its cytotoxicity. Studies have not yet investigated the effects of the combination of vorinostat and
cisplatin on small cell lung cancer (SCLC).
Methods: We first assessed the efficacy of vorinostat with etoposide/cisplatin (EP; triple combination) and then
investigated the effects of cotreatment with vorinostat and cisplatin on H209 and H146 SCLC cell lines. The
anticancer effects of various combinations were determined in terms of cell viability, apoptosis, cell cycle
distribution, and vorinostat-regulated proteins. We also evaluated the efficacy of vorinostat/cisplatin combination in
H209 xenograft nude mice.
Results: Our data revealed that the triple combination engendered a significant reduction of cell viability and high
apoptotic cell death. In addition, vorinostat combined with cisplatin enhanced cell growth inhibition, induced
apoptosis, and promoted cell cycle arrest. We observed that the acetylation levels of histone H3 and α-tubulin were
higher in combination treatments than in vorinostat treatment alone. Moreover, vorinostat reduced the expression
of thymidylate synthase (TS), and TS remained inhibited after cotreament with cisplatin. Furthermore, an in vivo
study revealed that the combination of vorinostat and cisplatin significantly inhibited tumor growth in xenograft
nude mice (tumor growth inhibition T/C% = 20.5 %).
Conclusions: Combined treatments with vorinostat promote the cytotoxicity of cisplatin and induce the expression
of vorinostat-regulated acetyl proteins, eventually enhancing antitumor effects in SCLC cell lines. Triple
combinations with a low dosage of cisplatin demonstrate similar therapeutic effects. Such triple combinations, if
applied clinically, may reduce the undesired adverse effects of cisplatin. The effects of the combination of vorinostat
and cisplatin should be evaluated further before conducting clinical trials for SCLC treatment.
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Background
Lung cancer is one of the leading causes of all-cancer mor-
tality. Small cell lung cancer (SCLC), which accounts for
10–15 % of all lung cancers [1], is the most aggressive cell
type because of its short doubling time, early widespread
metastases, and early relapse [2]. The standard first-line
chemotherapy regimen for patients with SCLC is etoposide
plus cisplatin (EP), and a response rate of 50–85 % can be
achieved initially [3–5]. However, patients can barely toler-
ate 6 cycles of the EP regimen because of its severe adverse
effects including myelosuppression, nephrotoxicity, and
ototoxicity [6, 7]. Moreover, topotecan, the only available
second-line US Food and Drug Administration (FDA)-ap-
proved drug for SCLC relapse or progression, is associated
with much lower response rates compared with the EP
regimen [2]. Because of the lack of a major breakthrough in
targeting SCLC treatments, therapeutic options have
remained largely unchanged over 3 decades [8]. The overall
5-year survival rate in SCLC remains less than 7 %, and
most patients hardly survive for 1 year after diagnosis des-
pite undergoing aggressive chemotherapy and radiotherapy
[2]. Therefore, a novel therapeutic strategy with less adverse
effects is urgently required for patients with SCLC.
In lung cancer, epigenetic aberrations have been linked to
oncogenesis, and potential therapeutic targets can be identi-
fied by understanding various epigenetic modifications [9].
Epigenetic changes in lung cancer cells are typically exem-
plified by nucleosomal histone modifications occurring
through the acetylation or deacetylation of N-terminal
histone tails [10]. Two antagonistic enzymes are associated
with this regulation to balance gene expressions: (1) histone
acetyltransferases (HATs) that relax the chromatin struc-
ture, activating chromatin and promoting gene transcrip-
tion; and (2) histone deacetylases (HDACs) that prevent the
binding of transcription factors to DNA, thus repressing
gene expression [11]. HDACs remove the acetyl group from
histone tails and cause the histone to twist around DNA,
thereby interfering with tumor suppressor gene transcrip-
tion [12]. Recent studies have identified various point muta-
tions in genes encoding histone modifiers in SCLC [13] and
have reported that the disruption of histone modifications is
a common feature in lung cancer cells [9]. Apart from
acetylation, another epigenetic modification associated with
the recruitment of the HDAC complex is the hypermethyla-
tion of promoter CpG islands, which is probably related to
a more aggressive phenotype [10, 14]. To date, extensive
research has focused on investigating inhibitors that target
epigenetic-related enzymes for regulating gene expressions
[15]. Therefore, HDAC inhibitors (HDACIs) have gained in-
creasing attention in recent years because of their capability
to restore tumor suppressor gene expression [16].
HDACIs have demonstrated anticancer effects by
selectively inducing apoptosis through modulating the
expression of proapoptotic and antiapoptotic genes in
cancer cells [17]. Upon binding of HDACIs to HDACs,
the accumulation of acetylated proteins including
histones engenders multiple cellular effects such as
apoptosis, cell cycle arrest, and angiogenesis inhibition.
In addition, HDACIs have demonstrated additive or syn-
ergistic effects when used with various anticancer agents
[18]. Vorinostat (suberoylanilide hydroxamic acid or
SAHA) is the first FDA-approved HDACI, and its effi-
cacy for treating refractory primary cutaneous T-cell
lymphoma was demonstrated [19]. In addition, the
preclinical applications of vorinostat to other cancers
(such as breast cancer and prostate cancer), as mono-
therapy or in combination, have been extensively investi-
gated [20–22]. In non-small cell lung cancer (NSCLC),
vorinostat in combination with cisplatin demonstrated
synergistic anticancer effects in vitro and in animal stud-
ies [23]. This thus prompted the execution of a clinical
phase I trial; it has just been completed and the final
results are still pending. Studies have reported that
vorinostat in combination with topotecan demonstrated
synergistic anticancer effects in SCLC [24, 25]. However,
information regarding the application of vorinostat treat-
ments is still limited. Other HDACIs such as panobinostat
and valproate have been reported to exhibit cytotoxicity
when used as monotherapy or enhanced anticancer efficacy
when paired with the EP regimen in SCLC cells [26, 27].
These studies have suggested that HDACIs can serve as
ideal anticancer agents for treating SCLC.
To the best of our knowledge, the anticancer effect of
vorinostat in combination with cisplatin on SCLC cells
has yet to be reported. Because cisplatin-based chemo-
therapy is the most commonly used regimen for treating
SCLC, we investigated whether vorinostat can enhance
cisplatin-mediated cell toxicity in SCLC in vitro and in
vivo. We believe that the results of this study may shed
some light on the development of a new treatment strat-
egy for SCLC in the near future.
Methods
Materials
Vorinostat (purity >99 %) was purchased from AbMole
BioScience (Houston, TX, USA); cisplatin (purity >99 %)
and etoposide (purity >99 %) were purchased from Selleck
Chemicals (Houston, TX, USA). These drugs were first
dissolved in 100 % dimethyl sulfoxide (DMSO) with a
stock concentration of 20 mM, and they were prepared
for cell experiments at final DMSO concentrations of less
than or equal to 1 %.
Cell culture
Human SCLC cell lines (H209 and H146) were obtained
from the Bioresource Collection and Research Center
(Hsinchu, Taiwan). The SCLC cells were cultured in
Iscove’s modified Dulbecco’s medium (IMDM; H209) or
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Roswell Park Memorial Institute-1640 medium (RPMI-
1640; H146) supplemented with 10 % fetal bovine serum
(FBS; v/v) and penicillin (100 unit/mL) or streptomycin
(100 μg/mL) and maintained at 37 °C in a humidified
incubator under a standard gas atmosphere of 5 % CO2.
Cell viability assay
Cell viability was examined using the MTS colorimetric
assay (CellTiter 96® AQueous One Solution Cell Proliferation
Assay, Promega, Madison, WI, USA). The cells were
cultured in 96-well microplates at 6 × 104 cells/well (H209)
or 4 × 104 cells/well (H146) with 100 μL of 10 % FBS-
supplemented medium per well for 24 h, and they were
then treated with indicated drugs for 24 h in triplicate.
Subsequently, 20 μL of MTS was added into each well and
incubated at 37 °C for 4 h. Furthermore, the absorbance
was measured at 490 nm by using the Molecular Devices
VersaMax tunable microplate reader (Molecular Devices,
Sunnyvale, CA, USA).
Western blot analysis
The cells were plated on 60-mm dishes at a density of 2 ×
106/dish (H209) or 1.5 × 106/dish (H146) for 24 h. After
24-h treatments with indicated drugs, the cells were
washed with cold phosphate-buffered saline (PBS), and
the cell pellet was lysed in 80 μL of lysis buffer (20 mM
Hepes, pH 7.9, 1 % (w/v) Triton X-100, 20 % (w/v)
glycerol, 1 mM ethylenediaminetetraacetic acid (EDTA),
1 mM ethylene glycol tetraacetic acid (EGTA), 20 mM
NaF, 1 mM dithiothreitol (DTT), 1 mM Na3VO4, 1 μg/mL
phenylmethylsulfonyl fluoride (PMSF), 1 μg/mL leupeptin,
and 1 μg/mL pepstatin). The protein concentration of the
cell lysates was measured using a Bradford protein assay
kit (Bio-Rad, Hercules, CA, USA) according to the manu-
facturer’s instructions. Subsequently, equal amounts of
total protein were loaded in each lane for sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (8 % or 12 %
polyacrylamide), and electrophoresis was started with an
initial voltage of 80 V in the stacking gel, followed by
110 V in the resolving gel by using the Bio-Rad Mini--
PROTEAN® Tetra gel system.
After electrophoresis, proteins were transferred onto
polyvinylidene fluoride membranes (Pall Life Science, Port
Washington, NY, USA) with a transfer buffer (20 mM
Tris-HCl, 150 mM glycine, and 20 % methanol) at
250 mA for 90 min; blocked with 5 % nonfat milk in Tris-
buffered saline Tween-20 (TBST), 20 mM Tris-HCl,
2.5 mM KCl, 150 mM NaCl, and 0.05 % (v/v) Tween-20
(pH 7.5); and incubated with primary antibodies of
interest in the blocking solution at 4 °C overnight. The
antibodies PARP-1 (#sc-7105, rabbit polyclonal, 1:500),
α-tubulin (#sc-12462-R, E-19, rabbit polyclonal, 1:1,000),
acetyl-α-tubulin (#sc-23950, mouse polyclonal, 1:500), and
β-actin (#sc-47778, mouse polyclonal, 1:5,000) were
purchased from Santa Cruz Biotechnology (Dallas, TX,
USA); acetyl-histone H3 (#9671S, Lys9, rabbit polyclonal,
1:1,000) was purchased from Cell Signaling Technology
(Danvers, MA, USA); and thymidylate synthase (TS,
#GTX62679, rabbit monoclonal, 1:500) was purchased
from GeneTex (Irvine, CA, USA). After the incubation
process, the membrane was sequentially washed twice
with TBST for 10 min each at room temperature and
hybridized with horseradish peroxidase-conjugated goat
antirabbit or goat antimouse IgG secondary antibodies
(Thermo Scientific, Waltham, MA, USA) at room
temperature for 1 h, and it was then washed 3 times with
TBST for 10 min each at room temperature. Thereafter,
the specific antibodies were detected using the
SuperSignal® West Pico chemiluminescent substrate
(Thermo Fisher Scientific, Waltham, MA, USA) according
to the manufacturer’s instructions, and signals were
visualized using an X-ray film (Fuji-RX, Tokyo, Japan).
Apoptosis assay
Drug-induced apoptosis was performed using the
Caspase-3/CPP32 colorimetric assay kit (BioVision,
Milpitas, CA, USA), which quantified the activity of
caspases by recognizing the sequence of DEVD. The
H209 (2 × 106 cells/dish) or H146 (1.5 × 106 cells/dish)
cells were seeded in 60-mm dishes for 24 h and treated
with the indicated drugs for 24 h (H209 and H146 cells)
or 36 h (H209 cells), and cell lysates were then prepared
in a cell lysis buffer following the manufacturer’s instruc-
tions. The cell lysates (200 μg) in 50 μL of the cell lysis
buffer were treated with 5 μL of the DEVD-pNA
substrate in 50 μL of 2× reaction buffer and incubated at
37 °C for 2 h in the dark. Finally, the absorbance was
measured at 405 nm by using the Molecular Devices
VersaMax tunable microplate reader.
Flow cytometric cell cycle analysis
Cell cycle fractions were assessed through propidium
iodide (PI; Sigma-Aldrich, St. Louis, MO, USA) nuclear
staining. The cells were seeded at 2 × 106 cells/dish
(H209) or 1.5 × 106 cells/dish (H146) in 60-mm dishes
for 24 h, and they were exposed to drug treatments for
24 h in 3 independent studies. After the drug treat-
ments, the cells were harvested, washed twice with cold
PBS, and centrifuged at 4 °C and 300 g for 5 min. The
supernatant was discarded and 1 × 106 cells were fixed in
1 mL of ice-cold 70 % ethanol at −20 °C overnight.
Furthermore, the cells were centrifuged at 4 °C and
300 g for 5 min, and the supernatant was discarded. The
cell pellets were stained with 500 μL of PBS containing
PI (50 μg/mL) and RNase A (50 μg/mL, Sigma-Aldrich)
at room temperature in the dark for 30 min. Cell cycle
distribution was analyzed through BD Accuri C6 flow
cytometry (BD Biosciences, San Jose, CA, USA).
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In vivo studies
All animal protocols were approved by the Institutional
Animal Care and Use Committee of the National Chiao
Tung University, Hsinchu, Taiwan. We used 6-week-old
male athymic nude mice (BALB/cAnN.Cg-Foxn1nu/
CrlNarl), group housed (five mice per cage) under the
condition of a 12-h light/dark cycle at 21–23 °C and
50–60 % humidity.
For implantation, one million H209 cells were har-
vested during the log-phase growth and resuspended
in IMDM medium with Matrigel (BD, Franklin Lakes,
NJ, USA) at a ratio of 1:1. Cells were then subcutane-
ously injected into the flanks of the mice. Once the
tumor volume reached 100 mm3, the mice were
randomized into four groups and administered the
following agents through intraperitoneal injections: (I)
vehicle, (II) vorinostat (at a dosage of 40 mg/kg body
weight administered 4 times a week; vorinostat was
first dissolved in DMSO and then added to a deion-
ized solution with 5 % (v/v) polyethylene glycol 400
(PEG 400) and 5 % (v/v) Tween-80, and the final
concentration of DMSO was 10 %), (III) cisplatin (at
a dosage of 1.5 mg/kg body weight administered once
a week; cisplatin was first dissolved in DMSO and
then added to PBS, and the final concentration of
DMSO was 1 %), and (IV) combination of cisplatin
and vorinostat (cisplatin at a dosage of 1.5 mg/kg
body weight administered on the first day of the
week, and vorinostat at a dosage of 40 mg/kg body
weight administered in the next 4 days of the week;
preparations of each agent were the same as in the
single-treatment group). Tumor growth was moni-
tored daily, and tumor volume (mm3) was defined as
(l x w2)/2, where l is the length and w is the width
(mm) of the tumor. The treatment was continued for
5 days, and the mice were euthanized 4 h after the
final dose. According to the US National Cancer In-
stitute protocols, tumor growth inhibition (T/C%) was
calculated using the formula [(average volume of a
treated group)/(average volume of a control group)] ×
100 %; T/C% equal to or less than 42 % is considered
significant antitumor activity.
Statistical analysis
Statistical and graphical analyses were performed using
GraphPad Prism 5 (GraphPad Software, La Jolla, CA,
USA). A graphical representation of the Western blot
analysis was quantified using ImageJ (US National
Institutes of Health, Bethesda, Maryland, USA). Results
were reported as mean ± standard deviation of the
indicated number of independent experiments. P values
were analyzed using ANOVA, and P < 0.05 was
considered significant.
Results
Triple combination treatments of vorinostat with EP
effectively inhibit cell growth and induce apoptosis in
SCLC cells
On the basis of the current clinical chemotherapy regimen
used for treating patients with SCLC, we first investigated
whether vorinostat in combination with EP can enhance
cell growth inhibition and cause cell apoptosis. Compared
with the treatment with vorinostat alone or EP, the triple
combination treatments with 0.8 μM vorinostat, 1 μM
cisplatin, and 1 μM etoposide (cisplatin:etoposide = 1:1)
were more effective in inhibiting the viability of the H209
(25.05 %) and H146 (16.10 %) cells (Fig. 1a). After the
adjustment of the concentration ratio of cisplatin to
etoposide (0.2 μM:0.6 μM= 1:3), the triple combination
treatment involving the addition of 0.4 μM vorinostat was
determined to be more effective in inhibiting the cell via-
bility (H209 at 32.74 % and H146 at 49.19 %), compared
with the treatment involving vorinostat alone or EP
(Fig. 1b). Moreover, through Western blot, we assessed
cleaved PARP protein levels to analyze the degree of cell
apoptosis. Compared with the cells exposed to vorinostat
alone or EP, the PARP cleavage was significantly enhanced
in the H209 and H146 cells treated with the triple
combination of 0.8 μM vorinostat and 1 μM cisplatin and
etoposide (Fig. 1c). In addition, the cleaved PARP protein
level was higher in the H209 and H146 cells treated with
the triple combination of vorinostat (0.4 μM) and EP
(0.6 μM:0.2 μM=3:1) than in those treated with vorino-
stat alone or EP (Fig. 1d). Overall, these results indicated
that the triple combination treatment enhanced cytotoxic
effects and promoted apoptosis in SCLC cells.
Vorinostat in combination with cisplatin effectively
impairs the viability of SCLC cells
To explore whether vorinostat enhances cisplatin-based
cytotoxicity, we examined cell viability by using the
MTS assay. The H209 and H146 SCLC cells were
treated with vorinostat alone, cisplatin alone, or in
combination. The combination treatments were more
effective in inhibiting H209 cell viability in a dose-
dependent manner (Fig. 2a). The cell viabilities achieved
when vorinostat at 0.1 and 0.5 μM was combined with
cisplatin at 5 μM were 79.28 and 42.33 %, respectively.
These data were significantly lower than those obtained
with any agent alone. Similarly, the measured cell
viability decreased in a dose-dependent manner in H146
cells; specifically, the cell viabilities observed when the
cells were treated with combinations of cisplatin at
5 μM and vorinostat at 0.1 or 0.2 μM were 80.21 and
68.81 %, respectively (Fig. 2b). These results indicated
that compared with any agent alone, combination
treatments were more effective in inhibiting the growth
of the SCLC cell lines.
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Combination of vorinostat and cisplatin enhances
apoptosis in SCLC cells
Because the combination treatment of vorinostat and
cisplatin significantly inhibited cell growth, we investi-
gated whether the enhanced cytotoxicity was due to cell
apoptosis. To examine cell apoptosis, we measured
cleaved PARP protein levels through Western blot
analysis and evaluated caspase-3 activity levels by using
the Caspase-3 assay kit. As presented in Fig. 3a, PARP
protein cleavage barely occurred in the H209 cells
treated with vorinostat alone (0.1 or 0.5 μM) or with
cisplatin alone (1 or 5 μM). By contrast, PARP protein
cleavage occurred in a dose-dependent manner when
the cells were treated with vorinostat in combination
with cisplatin. Similarly, PARP protein cleavage in-
creased in a dose-dependent manner in the H146 cells
treated with combinations of 0.05, 0.1, or 0.2 μM
vorinostat and 5 μM cisplatin (Fig. 3b). The results of
the caspase-3 assay revealed that the combined
treatment of 0.1 μM vorinostat and 5 μM cisplatin
significantly activated caspase-3 in the H209 cells treated
for both 24 and 36 h (Fig. 3c). The caspase-3 activity
Fig. 1 Effects of triple combination treatments of vorinostat with cisplatin and etoposide on the viability and apoptosis of SCLC cells. H209 and
H146 cells were treated with or without vorinostat in combination with cisplatin (a vorinostat at 0.8 μM, and cisplatin and etoposide both at
1 μM; b vorinostat at 0.4 μM, cisplatin at 0.2 μM, and etoposide at 0.6 μM) for 24 h. Cell viability was determined using the MTS assay, and data
were represented as mean ± SD in triplicate. A significant reduction in cell viability was documented (*, P < 0.05; **, P < 0.01; ***, P < 0.001)
compared with vorinostat or cisplatin/etoposide alone. c, d PARP cleavage was used for determining apoptosis. The cells were treated with the
same triple combination treatment described previously for 24 h, and cell lysates were collected and subjected to Western blot analysis with
PARP and α-tubulin
Fig. 2 Enhanced antigrowth activity of vorinostat combined with cisplatin in SCLC cells. a H209 and b H146 cells were treated with various
concentrations of vorinostat (0.1 and 0.5 μM and 0.1 and 0.2 μM, respectively), cisplatin alone (5 μM), and combinations of the 2 drugs for 24 h.
Cell viability was assessed using the MTS assay, and data were represented as mean ± SD in triplicate. A significant reduction in cell viability was
documented (*, P < 0.05; ***, P < 0.001) compared with that in vorinostat or cisplatin alone
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level observed after treatment for 36 h was increased by
3.1-fold relative to that observed after treatment with
vorinostat alone and by 1.7-fold relative to that observed
after treatment with cisplatin alone (Fig. 3c, right panel).
Similarly, in the H146 cells, the 24-h combination treat-
ment increased the caspase-3 activity level by 13.9-fold
compared with that by vorinostat treatment alone and
by 9.0-fold compared with that by cisplatin treatment
alone (Fig. 3d). Therefore, our data indicated that the
combination treatment dose dependently increased
apoptosis in the proteolytic cleavage of PARP and
activated caspase-3 in SCLC cells.
Cell cycle arrest analysis of vorinostat in combination
with cisplatin in SCLC cells
According to the growth inhibition results, we evaluated
the effects of the combination of vorinostat and cisplatin
on cell cycle progression. Flow cytometry was applied to
analyze the cell cycle distribution in PI-stained cells treated
with 0.1 μM vorinostat, 5 μM cisplatin, or a combination of
both agents. The H209 cells treated with vorinostat did not
have remarkable cell cycle arrest; however, those treated
with cisplatin or a combination of vorinostat and cisplatin
had cell cycle arrest in the S phase (Fig. 4a and c). The
H146 cells treated with vorinostat demonstrated no distinct
cell cycle arrest, whereas those treated with cisplatin exhib-
ited cell cycle arrest in the S phase (Fig. 4b and d). Similarly,
the combination treatment induced cell cycle arrest in the
S phase in the H146 cells. These data suggested that the
inhibition of cell growth engendered by the combination
treatment of vorinostat and cisplatin was through cell cycle
arrest in the S phase in the H209 and H146 cells.
Effects of combination treatments on vorinostat-
regulated proteins in SCLC cells
We investigated the effect of combination treatments on
specific protein expressions regulated by vorinostat. The
cells were incubated with vorinostat alone (0.1, 0.25, or
0.5 μM in H209 cells; 0.05, 0.1, or 0.2 μM in H146 cells),
cisplatin alone (5 μM), or combination of vorinostat at
various concentrations and cisplatin (5 μM) for 24 h.
Subsequently, protein expressions were analyzed through
Western blot. A general feature of vorinostat is its ability to
acetylate proteins [28]. Therefore, we examined the effects
of vorinostat alone and in combination treatments on
α-tubulin and histone H3 acetylation. The H209 cells
treated with 0.1 μM vorinostat demonstrated α-tubulin and
histone H3 acetylation, and the amount of acetylation in-
creased at 0.25 and 0.5 μM in a dose-dependent manner.
By contrast, the H209 cells treated with 5 μM cisplatin had
less acetylation of α-tubulin and no acetylation of histone
H3. However, we observed a significant dose-dependent en-
hancement of α-tubulin and histone H3 acetylation in the
cells treated with a combination of vorinostat and cisplatin
(Fig. 5a). Similar results were observed in the H146 cells.
We observed that high levels of acetyl α-tubulin and acetyl
histone H3 were induced with increasing doses of
vorinostat combined with cisplatin (Fig. 5b). Vorinostat can
suppress the expression of thymidylate synthase (TS) [29].
As presented in Fig. 5a and b, vorinostat alone induced a
Fig. 3 Vorinostat plus cisplatin triggers apoptotic cell death in SCLC cells. a H209 and b H146 cells were exposed to vorinostat or cisplatin alone
and in combination with these 2 agents for 24 h. Cell lysates were collected and subjected to Western blot analysis with PARP and α-tubulin. In
the caspase-3 activity assay, cells were treated with vorinostat alone (0.1 μM), cisplatin alone (5 μM), and in combination for c 24 and 36 h (H209)
or d 24 h (H146). DEVDase activity was represented as mean ± SD in 3 independent studies. A significant induction of DEVDase activity was
documented (*, P < 0.05; **, P < 0.01; *** P < 0.001) compared with that in vorinostat alone, cisplatin alone, or DMSO control
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dose-dependent reduction of TS protein levels in the H209
and H146 cells. After the combination treatment with vori-
nostat and cisplatin, the expression of TS was also inhibited
in a dose-dependent manner. On the basis of these find-
ings, vorinostat induced α-tubulin and histone H3 acetyl-
ation and enhanced the acetylation when cotreated with
cisplatin without affecting the inhibition of TS expression.
In vivo antitumor activity of combined vorinostat and
cisplatin in H209 xenografts
In accordance with the in vitro study, we observed that
combination treatment significantly inhibited cell growth,
caused cell cycle arrest, and induced cell apoptosis in the
H209 SCLC cells. We evaluated the antitumor effects of
combination treatment in vivo by using H209 xenografted
immunodeficient nude mice. Once the tumor size reached
approximately 100 mm3, the mice were randomly allo-
cated to a control group and 3 treatment groups to receive
therapeutic dosages of vorinostat (40 mg/kg), cisplatin
(1.5 mg/kg), a combination of both agents, or control
vehicles for 5 days. As presented in Fig. 6, compared with
vehicle and single-agent treatments, the combination
treatment significantly inhibited tumor growth at day 5.


































Fig. 4 Cell cycle progression analysis of vorinostat in combination with cisplatin in SCLC cells. a H209 and b H146 cells were treated with
vorinostat (0.1 μM), cisplatin alone (5 μM), and a combination of these 2 agents for 24 h, and the cell cycle distribution was analyzed through
flow cytometry. c, d Statistical analysis of cell cycle distribution was represented as mean ± SD in 3 independent studies. A significant arrest in the
cell-cycle phase was documented (*, P < 0.05; **, P < 0.01) compared with that in DMSO
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significant growth inhibitory effect compared to the
vehicle (T/C% = 100 %) and vorinostat group (T/C% =
102.4 %), but not to the cisplatin treatment group (T/C% =
47.0 %). During the treatment period, the mice tolerated all
the treatments without significant body weight differences.
In the in vivo study, the combination treatment of vorino-
stat and cisplatin remarkably reduced the tumor volume,
compared with vorinostat treatment alone.
Discussion
In this study, we observed that vorinostat enhanced the
therapeutic effects of cisplatin on H209 and H146 cell
lines. Cisplatin interacts with DNA to form DNA
intrastrand crosslink adducts, inducing apoptotic cell
death [30]. When cisplatin is combined with vorinostat,
the relaxation of the chromatin structure induced by
vorinostat facilitates the accessibility of DNA to cis-
platin, thereby significantly enhancing its cytotoxicity
[31]. As expected, the inhibition of cell growth was
higher with combination treatment than with any agent
alone (Fig. 2). Moreover, we observed enhanced apop-
tosis through examining the cleaved PARP protein levels
as well as caspases-3 activity (Fig. 3). Similar
enhancements of the anticancer effects of vorinostat and
cisplatin combinations on HeLa cells and oral squamous
cell carcinoma cell lines have been reported [32, 33].
Overall, these results suggest that vorinostat
combinations potentially improve the chemotherapeutic
outcomes of cisplatin.
In our study, the most difficult decision was determin-
ing the dosage of different drugs in triple combination.
The EP regimen is commonly administered at a dosage
of 80 mg/m2 cisplatin (1 day/cycle) and 100 mg/m2
etoposide (3 days/cycle) [34, 35], and patients with a
limited stage of disease treated with thoracic radiother-
apy additionally, when exhibited a complete response.
Fig. 5 Effects of cotreatments on vorinostat-regulated signaling molecules in SCLC cells. a H209 and b H146 cells were treated with indicated
concentrations of vorinostat (0.1, 0.25, and 0.5 μM and 0.05, 0.1, and 0.2 μM, respectively), cisplatin alone (5 μM), and a combination of these 2




Fig. 6 Antitumor activity of combined vorinostat and cisplatin in H209 xenografts. Immunodeficient nude mice bearing subcutaneously
established H209 xenograft tumors were randomized to 4 groups and received the indicated treatments: (I) vehicle, (II) vorinostat (dosage of
40 mg/kg body weight, administered 4 times a week), (III) cisplatin (dosage of 1.5 mg/kg body weight, administered once a week), and (IV)
combination (cisplatin at a dosage of 1.5 mg/kg body weight, administered once a week; vorinostat at a dosage of 40 mg/kg body weight,
administered 4 times a week) through intraperitoneal injection. The therapy was started in an initial volume of 100 mm3 and tumors were
measured regularly. a Tumor growth curves were expressed as mean ± SD with the T/C% at day 5. b Tumor volumes in each group were shown
at day 5. A significant inhibition in tumor growth was documented (***, P < 0.001) compared with that in vorinostat or vehicle
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Because the direct application of clinical settings to cell
line studies is difficult, we mimicked the concentration
ratio of these 2 agents on the basis of the clinical dosage
and treatment cycle. We adjusted the proportion of
cisplatin/etoposide to 1:1 and 1:3, in combination with
vorinostat. In addition, our previous data have shown
that the 24-h IC50 values of vorinostat were 1.3 and
1.0 μM in the H209 and H146 cells, respectively. To
evaluate whether relatively low dosages of drugs can
enhance anticancer effects when combined, we
purposely selected different concentrations, which were
lower than IC50 values (triple combination: 0.4 and
0.8 μM; cotreatments: 0.1–0.5 μM in the H209 cells and
0.05–0.2 μM in the H146 cells), to perform experiments
in the present study.
Notably, the concentration of vorinostat in triple
combinations (three drugs) was higher than that in
vorinostat/cisplatin (two drugs) combinations, and the
dosage of cisplatin in triple combinations was less than
80 % (1 μM in 3-drug treatments compared with 5 μM
in 2-drug treatments). Moreover, the dosages of cisplatin
used in our study (0.2 and 1 μM) are lower than that
used (10 μM) in similar HDACI-based EP combined
experiments in SCLC cell lines in a previous study [26].
According to our findings, lowering the dosage of
cisplatin did not minimize the ultimate cytotoxic effects.
Specifically, the viability of cells treated with triple com-
binations was significantly reduced (Fig. 1a and b; Fig. 2a
and b). These results suggest that the dosage of cisplatin
can be reduced by the addition of etoposide in the
presence of vorinostat. Accordingly, the new combined
regimen using a low dosage of cisplatin has a potential
benefit of minimizing nephrotoxicities and ototoxicities
[5]. However, this remains to be studied further before
its application in clinical settings.
We observed different caspase-3 activity levels in the 2
cell lines. In the H209 cells (Fig. 3c), the activation of
caspase-3 (cotreatment compared with single-agent
treatments) was not evident in cells treated for 24 h;
however, when the treatment duration was prolonged to
36 h, the activation of caspase-3 became apparent.
Furthermore, the 24-h cotreatment induced significantly
higher activation levels (13.9- and 9.0-fold) in the H146
cells (Fig. 3d) compared with those (3.1- and 1.7-fold)
induced by the 36-h cotreatment in the H209 cells.
Consistently, a study reported a relatively higher caspase
activity level in H146 cells than in other SCLC cells [26].
We speculate that this difference is attributable to
phenotypic variations.
The results of our cell cycle distribution analyses are in
contrast with those reported in the literature. Vorinostat
causes cell cycle arrest in the G0/G1 phase, whereas
cisplatin causes cell cycle arrest in the G2 phase [36, 37].
Our data reveal no obvious cell arrest when both cell lines
were treated with vorinostat alone and an S-phase arrest
when treated with cisplatin alone (Fig. 4). We consider
that these results are attributable to the relatively low
dosage of vorinostat and inheritance of different cell line
responses. In a study on combined treatment, cotreatment
of vorinostat and topotecan caused cell cycle arrest in the
S phase in SCLC cell lines [24]. Similarly, we observed cell
cycle arrest in the S phase in our combination treatments
with vorinostat and cisplatin (Fig. 4). The cytotoxic effect
of cisplatin peaks when cells are in the S phase [36].
Hence, we assumed that the enhanced cytotoxicity of
cotreatments is correlated with cell cycle arrest in the S
phase, which consequently leads to the inhibition of cell
growth and induction of apoptosis in SCLC cells.
Various vorinostat-regulated protein expressions, in-
cluding acetyl α-tubulin, acetyl histone H3, and TS, have
crucial roles in enhancing the efficacy of cotreatments.
As presented in Fig. 5, we observed that vorinostat
promoted histone H3 acetylation, and the histone H3
acetylation level dramatically increased when vorinostat
was combined with cisplatin in SCLC cells. Vorinostat
induces the hyperacetylation of core histones and
therefore relaxes the chromatin structure. In the case of
an open chromatin configuration, transcription factors
or drugs that target DNA can have more accessibility to
genomic DNA [9]. Our finding supports the hypothesis
that the enhanced apoptosis is likely due to the
increased accessibility of targeted DNA to cisplatin after
vorinostat treatment.
We observed that the acetylation of α-tubulin in-
creased in a dose-dependent manner when treated with
vorinostat. As anticipated, adding cisplatin increased the
acetylation of α-tubulin. The acetylated α-tubulin,
considered to be a part of stable microtubules, is a
nondynamic type of microtubules related to increased
cell stress and cell death [38]. These results suggest that
the anticancer efficacy of cotreatment is increased under
the condition of microtubule stabilization caused by
vorinostat, ultimately leading to cancer cell death.
In addition, we observed that vorinostat downregulated
TS protein levels, and TS protein remained inhibited
when combined with cisplatin. Vorinostat inhibited the
expression of TS, an essential enzyme for DNA synthesis
in cancer cells [39]. These data indicate that vorinostat is
still active in inhibiting TS expression in the combination
mode and can affect DNA synthesis to suppress cancer
cell growth. The modulation of TS expression by vorino-
stat offers an additional insight into the salient mecha-
nisms of the connection between vorinostat and cisplatin.
Finally, the enhanced antitumor effects of vorinostat
with cisplatin were confirmed by conducting an in vivo
study by using H209 tumor xenografts (Fig. 6). Notably,
the dosages of cisplatin and vorinostat used in this
animal study are lower [40, 41], which imply the
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possibilities of lowering the side effects without losing
their efficacy. In addition, sequential therapy enables the
optimal delivery of each drug and probably reduces the
risk of toxicity, thus improving the quality of life in
clinical settings [42]. The treatment strategy of our
animal study is exactly a sequential therapy. On the basis
of these in vitro and in vivo findings, we strongly suggest
that a clinical trial is warranted.
Conclusions
To the best of our knowledge, this is the first study con-
firming that vorinostat promotes cisplatin-mediated cell
toxicity in SCLC. The combination treatments exhibited
enhanced effectiveness levels in reducing cell growth,
inducing apoptosis, and regulating cell cycle arrest. More-
over, vorinostat-regulated acetyl protein expressions were
dramatically induced when vorinostat was combined with
cisplatin. In addition, the H209 xenograft models demon-
strated tumor growth inhibition in the combined therapy.
Moreover, this novel regimen of vorinostat and cisplatin
not only reduces tumor growth in vitro and in vivo but
also implies the possibility of minimizing adverse effects
of cisplatin. Overall, the preclinical data and results of our
study provide clinical implications for the development of
a new therapeutic design.
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